Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen's new weight loss drug, MariTide, shows up to 20% weight loss in trials, but faces competition from Eli Lilly and Novo ...